Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the insufficient production or release of digestive enzymes by the pancreas into the small intestine. These enzymes are crucial for the proper digestion and absorption of nutrients from ingested food. Exocrine pancreatic insufficiency can result in malnutrition and various digestive symptoms, such as diarrhea, abdominal pain, bloating, and weight loss.
The primary types of treatments for exocrine pancreatic insufficiency include nutritional management, pancreatic enzyme replacement therapy (PERT), and other interventions. Nutritional management involves planning and implementing dietary strategies to optimize an individual's nutritional status, supporting overall health and well-being. This approach is essential in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed through imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others. These diagnostic tests help identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, and weight loss. The drugs used for treating exocrine pancreatic insufficiency are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. These medications are utilized by end users such as hospitals, specialty clinics, and individuals receiving care at home.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The exocrine pancreatic insufficiency market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.
The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness and diagnosis, growing prevalence of digestive disorders, aging population, and pancreatic function decline, rise in gastrointestinal surgeries.
The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to continued increase in awareness and screening, expanding geriatric population, rising incidence of chronic diseases, improvements in patient access to healthcare, research and development in digestive health. Major trends in the forecast period include telehealth and digital health solutions, collaborative research initiatives, focus on pediatric epi, regulatory advances and fast-track designations, market expansion in emerging economies, advancements in healthcare infrastructure.
The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of pancreatic enzyme replacement therapies (PERT) sourced from Canada and Germany, thereby delaying digestive symptom relief and elevating gastroenterology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of chronic diseases is expected to drive the growth of the exocrine pancreatic insufficiency market in the future. Chronic diseases are long-term conditions that last for extended periods, typically over three months. The ongoing presence of these conditions can also heighten the risk of developing secondary complications, such as exocrine pancreatic insufficiency, which in turn promotes better management of chronic diseases through medical treatments and therapies, potentially extending the lives of affected individuals. For example, in September 2023, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% of these attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Consequently, the rise in chronic diseases will accelerate the growth of the exocrine pancreatic insufficiency market.
The escalating cases of diabetes are expected to fuel the growth of the exocrine pancreatic insufficiency market. Diabetes, a chronic health condition characterized by inadequate insulin production or utilization by the body, leads to an accumulation of excessive blood sugar in the bloodstream. Pancreatic enzyme replacement treatment (PERT) becomes essential to supply adequate digestive enzymes for exocrine pancreatic insufficiency (EPI) and maintain the body's insulin levels. For instance, a report from the Institute for Health Metrics and Evaluation in June 2023 projected global diabetes cases to reach 1.3 billion by 2050, up from 529 million in 2022. Therefore, the increasing prevalence of diabetes is expected to drive the growth of the exocrine pancreatic insufficiency market.
Leading companies in the exocrine pancreatic insufficiency market are focusing on establishing patient advocacy initiatives, such as offering comprehensive nutritional guidance and support. These efforts aim to raise awareness, educate, and improve the management of the condition for those affected. Comprehensive nutritional guidance is an all-encompassing approach that customizes dietary recommendations according to individual needs, health status, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For example, in June 2024, Nestle Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. This platform provides personalized nutritional resources and expert advice for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and general wellness. Its goal is to empower users on their weight management journey by addressing specific dietary needs and building community support.
In December 2023, Codexis, a US-based pharmaceutical company, acquired a division of Nestle Health Science for an undisclosed amount. Through this acquisition, Codexis aims to monetize its asset CDX-7108, concentrate on core projects, and leverage Nestle's expertise to expedite development while maintaining economic interest. Nestle Health Science, a Switzerland-based science-driven nutrition company, offers specialized nutritional products to aid individuals with exocrine pancreatic insufficiency by enhancing digestion and nutrient absorption.
Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics
North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Exocrine Pancreatic Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on exocrine pancreatic insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for exocrine pancreatic insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The exocrine pancreatic insufficiency market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Other Treatments
- 2) By Diagnosis: Imaging Tests; Computed Tomography (CT) Scan; Abdominal Ultrasound; Secretin Pancreatic Function Test; Fecal Fat Test; Fecal Elastase Test (FE-1); Other Types
- 3) By Symptoms: Abdominal Pain; Constipation; Diarrhea; Fatty Stools; Weight Loss; Other Symptoms
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
- 5) By End Users: Hospitals; Specialty Clinics; Homecare
- Subsegments:
- 1) By Nutritional Management: Dietary Modifications; Nutritional Supplements
- 2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules; Non-Enteric-Coated Capsules; Powder Formulations
- 3) By Other Treatments: Medications; Surgical Interventions; Supportive Therapies
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; AstraZeneca plc; Medtronic plc; Eli Lilly and Company; Gilead Sciences Inc.; Nestle Health Science S.A.; Allergan plc; Chiesi Farmaceutici S.p.A.; Wockhardt Ltd.; Amryt Pharma Plc; Codexis Inc.; Nordmark Arzneimittel GmbH & Co. KG; Aimmune Therapeutics Inc; Digestive Care Inc.; Enzymedica Inc.; Vivus Inc.; Alcresta Therapeutics Inc.; Cilian AG; Perseo Pharma AG; Enzyme Development Corporation; First Wave BioPharma Inc.; Synspira Therapeutics
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Exocrine Pancreatic Insufficiency Market Characteristics
3. Exocrine Pancreatic Insufficiency Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Exocrine Pancreatic Insufficiency Growth Analysis And Strategic Analysis Framework
- 5.1. Global Exocrine Pancreatic Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Exocrine Pancreatic Insufficiency Market Growth Rate Analysis
- 5.4. Global Exocrine Pancreatic Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Exocrine Pancreatic Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Exocrine Pancreatic Insufficiency Total Addressable Market (TAM)
6. Exocrine Pancreatic Insufficiency Market Segmentation
- 6.1. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nutritional Management
- Pancreatic Enzyme Replacement Therapy (PERT)
- Other Treatments
- 6.2. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imaging Tests
- Computed Tomography (CT) Scan
- Abdominal Ultrasound
- Secretin Pancreatic Function Test
- Fecal Fat Test
- Fecal Elastase Test (FE-1)
- Other Types
- 6.3. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Abdominal Pain
- Constipation
- Diarrhea
- Fatty Stools
- Weight Loss
- Other Symptoms
- 6.4. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other Distribution Channels
- 6.5. Global Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- 6.6. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Nutritional Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dietary Modifications
- Nutritional Supplements
- 6.7. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Enteric-Coated Capsules
- Non-Enteric-Coated Capsules
- Powder Formulations
- 6.8. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications
- Surgical Interventions
- Supportive Therapies
7. Exocrine Pancreatic Insufficiency Market Regional And Country Analysis
- 7.1. Global Exocrine Pancreatic Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Exocrine Pancreatic Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Exocrine Pancreatic Insufficiency Market
- 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Exocrine Pancreatic Insufficiency Market
- 9.1. China Exocrine Pancreatic Insufficiency Market Overview
- 9.2. China Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Exocrine Pancreatic Insufficiency Market
- 10.1. India Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Exocrine Pancreatic Insufficiency Market
- 11.1. Japan Exocrine Pancreatic Insufficiency Market Overview
- 11.2. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Exocrine Pancreatic Insufficiency Market
- 12.1. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Exocrine Pancreatic Insufficiency Market
- 13.1. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Exocrine Pancreatic Insufficiency Market
- 14.1. South Korea Exocrine Pancreatic Insufficiency Market Overview
- 14.2. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Exocrine Pancreatic Insufficiency Market
- 15.1. Western Europe Exocrine Pancreatic Insufficiency Market Overview
- 15.2. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Exocrine Pancreatic Insufficiency Market
- 16.1. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Exocrine Pancreatic Insufficiency Market
- 17.1. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Exocrine Pancreatic Insufficiency Market
- 18.1. France Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Exocrine Pancreatic Insufficiency Market
- 19.1. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Exocrine Pancreatic Insufficiency Market
- 20.1. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Exocrine Pancreatic Insufficiency Market
- 21.1. Eastern Europe Exocrine Pancreatic Insufficiency Market Overview
- 21.2. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Exocrine Pancreatic Insufficiency Market
- 22.1. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Exocrine Pancreatic Insufficiency Market
- 23.1. North America Exocrine Pancreatic Insufficiency Market Overview
- 23.2. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Exocrine Pancreatic Insufficiency Market
- 24.1. USA Exocrine Pancreatic Insufficiency Market Overview
- 24.2. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Exocrine Pancreatic Insufficiency Market
- 25.1. Canada Exocrine Pancreatic Insufficiency Market Overview
- 25.2. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Exocrine Pancreatic Insufficiency Market
- 26.1. South America Exocrine Pancreatic Insufficiency Market Overview
- 26.2. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Exocrine Pancreatic Insufficiency Market
- 27.1. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Exocrine Pancreatic Insufficiency Market
- 28.1. Middle East Exocrine Pancreatic Insufficiency Market Overview
- 28.2. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Exocrine Pancreatic Insufficiency Market
- 29.1. Africa Exocrine Pancreatic Insufficiency Market Overview
- 29.2. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Exocrine Pancreatic Insufficiency Market Competitive Landscape And Company Profiles
- 30.1. Exocrine Pancreatic Insufficiency Market Competitive Landscape
- 30.2. Exocrine Pancreatic Insufficiency Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Exocrine Pancreatic Insufficiency Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Novartis AG
- 31.3. Sanofi S.A.
- 31.4. AstraZeneca plc
- 31.5. Medtronic plc
- 31.6. Eli Lilly and Company
- 31.7. Gilead Sciences Inc.
- 31.8. Nestle Health Science S.A.
- 31.9. Allergan plc
- 31.10. Chiesi Farmaceutici S.p.A.
- 31.11. Wockhardt Ltd.
- 31.12. Amryt Pharma Plc
- 31.13. Codexis Inc.
- 31.14. Nordmark Arzneimittel GmbH & Co. KG
- 31.15. Aimmune Therapeutics Inc
32. Global Exocrine Pancreatic Insufficiency Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency Market
34. Recent Developments In The Exocrine Pancreatic Insufficiency Market
35. Exocrine Pancreatic Insufficiency Market High Potential Countries, Segments and Strategies
- 35.1 Exocrine Pancreatic Insufficiency Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Exocrine Pancreatic Insufficiency Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Exocrine Pancreatic Insufficiency Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
